October 31 – ** Shares of Sarepta Therapeutics SRPT.O fall 44.3% to $60 pre-market
** The company said Monday that its gene therapy to treat Duchenne muscular dystrophy (DMD), a progressive muscle disease, failed to meet the primary endpoint of a late-phase trial in patients aged 4 to 7 years
**The therapy received accelerated approval from the U.S. health regulator in June for children ages 4 to 5 who can walk
** Catalent CTLT.N , which makes SRPT’s gene therapy, also fell about 13.6% before markets closed
** Through last close, SRPT shares were down 17% and CTLT shares were down 11.3% year to date